Outlook Therapeutics (DB:41O) - Hisse Senedi Fiyatı, Haberler ve Analizler

41O Stoklara Genel Bakış

41O temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Kazançların yılda 56.39% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Negatif hissedar öz sermayesi

+ 1 daha fazla risk

Outlook Therapeutics, Inc. Rakipler

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

4SC

DB:VSC

€48.2m

Medigene

XTRA:MDG1

€22.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Outlook Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.82
52 Haftanın En Yüksek Seviyesi	US$9.52
52 Haftanın En Düşük Seviyesi	US$4.44
Beta	0.63
11 Aylık Değişim	-0.82%
3 Aylık Değişim	-28.06%
1 Yıllık Değişim	-34.86%
33 Yıllık Değişim	-78.09%
5 Yıllık Değişim	-73.22%
Halka arzdan bu yana değişim	-90.73%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	41O	DE Biotechs	DE Pazar
7D	-5.5%	-0.7%	-0.02%
1Y	-34.9%	-17.2%	8.2%

Getiri vs. Endüstri: 41O geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 41O geçen yıl % 8.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 41O's price volatile compared to industry and market?
41O volatility
41O Average Weekly Movement	9.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

İstikrarlı Hisse Senedi Fiyatı: 41O hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 41O 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	24	Russ Trenary	www.outlooktherapeutics.com

Klinik aşamada bir biyofarmasötik şirketi olarak faaliyet gösteren Outlook Therapeutics, Inc. çeşitli oftalmik endikasyonlar için monoklonal antikorlar geliştirmeye ve ticarileştirmeye odaklanmaktadır. Şirketin öncü ürün adayı, yaşlılığa bağlı makula dejenerasyonu ve diğer retina hastalıklarının tedavisi için Faz-III klinik çalışmasında olan bevacizumab ürün adayının oftalmik bir formülasyonu olan ONS-5010'dur. Outlook Therapeutics, Inc. şirketinin BioLexis Pte.

Outlook Therapeutics, Inc. Temel Bilgiler Özeti

Outlook Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
41O temel i̇stati̇sti̇kler
Piyasa değeri	€114.26m
Kazançlar(TTM)	-€90.32m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.3x

F/K Oranı

41O aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
41O gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$34.18m
Brüt Kâr	-US$34.18m
Diğer Giderler	US$59.86m
Kazançlar	-US$94.05m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.98
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-38.8%

41O uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

41O Stoklara Genel Bakış

Ödüller

Risk Analizi

Outlook Therapeutics, Inc. Rakipler

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

DB:VSC

€48.2m

XTRA:MDG1

€22.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Recent updates

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Forecast breakeven date moved forward to 2024

High number of new directors

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold €189k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought €112k worth of stock

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021